GeneThera (GeneThera) Float Percentage Of Total Shares Outstanding : 64.02% (As of May. 22, 2024)

View and export this data going back to 2000. Start your Free Trial

What is GeneThera Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GeneThera's float shares is 22.62 Mil. GeneThera's total shares outstanding is 35.33 Mil. GeneThera's float percentage of total shares outstanding is 64.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GeneThera's Insider Ownership is 0.03%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GeneThera's Institutional Ownership is 0.00%.

GeneThera Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

GeneThera's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	22.62	/	35.33
	=	64.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneThera (GeneThera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035

Website

http://genetherainc.com

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.

Executives

Avel Kolesnikov	director	11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr	10 percent owner	632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd	10 percent owner	CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner	director, officer: Chief Financial Officer	728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici	director, 10 percent owner, officer: Chief Executive Officer	3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry	director, 10 percent owner, officer: Chief Administative Officer	11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines